Dr. Reddy's Laboratories Limited

NYSE:RDY

Drug Manufacturers - Specialty & Generic

Healthcare
$14.98 -1.13%

-$0.15 today

Market cap
$12.48B
Beta
0.26
P/E (TTM)
24.7
EPS (TTM)
$51.40
Dividend yield
0.63%
52W Low $12.19High $15.71

Volume 1.79M

Average 2.39M

RDY Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Dr. Reddy's Laboratories LimitedNYSE: RDY

Depreciation & Amortization · Q2 FY2027 · quarter ended Sep 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q2 FY2027 depreciation & amortization of ₹5.26B rose 4.2% year over year, behind the +12.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 2.0% from the prior quarter. Over 3 fiscal years it compounded at +19.7% a year.

Context

  • Depreciation & amortization amounted to 6.1% of revenue in FY2026, up 0.9 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +4.2% toward the trailing-twelve-month pace of +12.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
₹5.26B-2.0% QoQ
Last fiscal yearMar 2026
₹21.68B+27.1% YoY
LTMSep 2026
₹21.51B+12.7% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.2%——
1 year+27.1%——
3-year CAGR+19.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

INR · from the cash flow

Latest · FY2026
21.68B INR
Year-over-year change
+27.1%
4-year CAGR
+16.4%

Depreciation & Amortization vs competitors

How RDY compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +12.7% is the 3rd highest of 8, against a peer median of +1.6%.
  • Depreciation & amortization amounts to 6.5% of revenue for RDY, versus a peer median of 8.0%.
RDY Competitors
Depreciation & Amortization for RDY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹21.51B INR+12.7%+19.7%6.5%
VTRSViatris Inc.LTM Jun 2026$2.8B USD+1.6%-2.6%19.0%
BHCBausch Health Companies Inc.LTM Jun 2026$1.17B USD-5.6%-4.7%10.8%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$989M USD-3.3%-8.5%5.7%
HLNHaleon plcFY2025£352.11M GBP+8.7%+7.1%3.2%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$194.29M USD-20.8%-2.4%6.2%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$89.45M USD+17.8%+15.3%9.7%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$57.48M USD+44.0%+30.0%8.0%
Peer median (excluding RDY) —+1.6%-2.4%8.0%

Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

INR
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income23.57B45.07B55.68B57.25B45.09B
Depreciation & Amortization11.82B12.64B14.84B17.06B21.68B
Deferred Income Tax8.73B15.3B16.19B19.54B0
Stock-Based Compensation592M397M407M424M0
Change in Working Capital(13.91B)(7.86B)(20.18B)(29.99B)(12.24B)
Accounts Receivables(17.01B)(5.75B)(8.05B)(10.28B)(7.07B)
Inventory(5.33B)(2.65B)(18.45B)(12.75B)(9.05B)
Accounts Payables17.01B0002.94B
Other Working Capital(8.59B)551M6.32B(6.95B)943.83M
Other Non-Cash Items(2.69B)(6.67B)(21.5B)(17.85B)2.12B
Operating Cash Flow28.11B58.88B45.43B46.43B56.65B
Capital Expenditures(19.05B)(18.87B)(27.44B)(34.4B)(24.54B)
Acquisitions (Net)(326M)0(12M)(53.41B)(2.99B)
Purchases of Investments(88.97B)(136.17B)(145.49B)(254.46B)(49.21B)
Sales of Investments77.77B112.81B129.78B279.58B20.63B
Other Investing Activities4.19B(6.68B)(8.16B)(2.28B)1.47B
Investing Cash Flow(26.39B)(41.37B)(40.28B)(58.08B)(70.53B)
Debt Repayment2.74B(20.4B)4.35B23.2B21.31B
Common Stock Issued334M368M805M193M417.73M
Common Stock Repurchased000(1.39B)0
Dividends Paid(4.15B)(4.98B)(6.65B)(6.66B)(7.01B)
Other Financing Activities(1.35B)(1.85B)(2.27B)3.57B(1.33B)
Financing Cash Flow(2.42B)(26.86B)(3.76B)18.91B13.4B
Effect of Forex Changes733M286M(59M)224M(383.41M)
Net Change in Cash32M(9.07B)1.33B7.49B(875.84M)
Free Cash Flow9.06B40.01B18B12.03B32.1B

Dr. Reddy's Laboratories Limited

NYSE:RDY

Intrinsic Alpha fair value

Locked

Current Price

$14.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.